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ABSTRACT 
 
 
Sakaram, Suraj. M.S. Department of Biochemistry and Molecular Biology, Wright State 
University, 2016. Delineating ΔNp63α’s function in epithelial cells. 
 
 
DNp63a, the most physiologically relevant isoform of p63, a p53 family member protein, 
maintains the proliferative capacity of the basal layer of epithelial tissues and is highly expressed 
in non-melanoma skin cancer. It has been implicated in a variety of different cancers, including 
breast, lung, and prostate cancers, however the complex role it plays in disease remains poorly 
understood. Elucidating DNp63a’s regulatory network may provide insight into its role in 
epithelial tissues and in cancer progression. The objective of this thesis is to investigate DNp63a’s 
upstream regulation in the context of non-melanoma skin cancer as well as expand on DNp63a’s 
downstream function through its modulation of target microRNAs (miRNAs). 
 Non-melanoma skin cancer is primarily a result of excessive exposure to ultraviolet (UV) 
radiation. DNp63a appears to be regulated by post-translational modifications such as 
phosphorylation, which can lead to its degradation in a ubiquitin-mediated, proteasome-dependent 
manner. cJun N-terminal kinase (JNK), a stress activated protein kinase (SAPK), is potently 
activated by UV stress and has been shown to phosphorylate p53 and p73. I hypothesized that UV-
induced JNK activation can similarly regulate DNp63a via phosphorylation. Anisomycin and UV 
induced JNK activation were shown to produce an electrophoretic mobility shift in ΔNp63α, 
suggesting it was phosphorylated. Co-expression of JNK and ΔNp63α also exhibited an enhanced 
electrophoretic mobility shift in ΔNp63α following UV and anisomycin treatment. 
Phosphorylation was confirmed using an in vitro kinase assay with recombinant JNK and p63 
proteins. Mass spectrometry analysis of immunoprecipitated ΔNp63α protein from UV treated 
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H1299 cells transfected with ΔNp63α and in vitro kinase assay samples identified several 
phosphorylated residues, some of which are highly conserved in p73. Mutation of these potential 
JNK targeted residues alone did not prevent an electrophoretic mobility shift, however, a 
combination of mutated residues resulted in a stabilization of ΔNp63α levels. These results 
suggest that JNK plays a role in the phosphorylation of ΔNp63α, implicating it as a potential 
mediator of ΔNp63α degradation and apoptosis.  
 ΔNp63α has been shown to regulate a number of miRNAs that affect a wide range of 
biological processes. Advances in high-throughput sequencing technologies have made it possible 
to profile differentially expressed miRNAs to gain insight into the role they play in the 
pathogenesis of cancer. Interestingly, although next-generation sequencing (NGS) platforms have 
become popular for studying miRNA expression profiles through small RNA-Seq, a consensus on 
the data processing methodology has not yet been reached. In this dissertation, I sought to both 
optimize and validate a pipeline for analyzing small RNA-Seq data and, with the resulting dataset, 
gain insight into the regulation of miRNA expression by ΔNp63α. A test NGS dataset was 
generated by sequencing small RNA from non-silencing control (NSC) and p63-silenced (sip63) 
HaCaTs cells using the Ion ProtonTM System. I optimized data collection and analysis parameters 
using this dataset and established a functional pipeline workflow involving alignment to the 
miRBase reference database, normalization using the Trimmed Mean of M-values (TMM) 
normalization method, and differential expression using a lognormal with shrinkage response 
distribution model. This pipeline configuration resulted in a shortlist of differentially expressed 
miRNAs which was enriched for known p63-regulated miRNAs, thus empirically confirming 
pipeline function. Finally, I validated the differential expression of several novel p63-regulated 
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miRNA including miRs-103a-3p, 149-5p, 18a-5p, 19b-1-5p, 590-5p, 598-3p, 7-5p, 708-5p, 744-
5p, and 93-5p. 
 In Summary, this study provides insight into JNK’s potential regulation of ΔNp63α via 
phosphorylation and downstream proteasomal degradation. As well, optimization of a small RNA-
Seq pipeline facilitated identification of novel ΔNp63α-regulated miRNAs and expanded our 
understanding of the role played by ΔNp63α in cancer progression. 
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I. INTRODUCTION 
 
A. DNp63a and the skin 
 p63 is a p53 family member protein that is primarily expressed in the basal layer of the 
epidermis and other epithelial tissues. It plays an integral role in developing these tissues and 
maintaining their proliferative capacity. The p63 gene contains an N-terminal transactivation 
domain (TA), a central DNA binding domain (DBD), and a C-terminal oligomerization domain 
(OD), sequences that share high homology to p53 and p73 (Yang, Kaghad et al. 1998). Due to 
alternative promoter usage and 3’-terminal splicing, p63 can be transcribed as multiple isoforms. 
Transcription initiated at the P1 promoter produces the full-length TA domain isoforms whereas 
transcription initiated at the internal P2 promoter produces the truncated TA domain (DN) 
isoforms. Differential 3’ splicing yields the full-length (a), or truncated (b or g) isoforms (Fig. 1) 
(Yang, Kaghad et al. 1998, Courtois, Caron de Fromentel et al. 2004). TAp63 isoforms function 
similarly to p53 by acting as tumor suppressors, while DNp63 isoforms antagonize p53 and 
TAp63-mediated transactivation of target genes. DNp63 can also transactivate select target genes 
(Senoo, Matsumura et al. 2002, Osada, Park et al. 2005, Kommagani, Caserta et al. 2006, Ortt, 
Raveh et al. 2008, Marinari, Ballaro et al. 2009). 
 p63 is essential for proper development of limbs and stratified epithelium as was 
demonstrated in p63 null mice which lacked skin and limbs, and died shortly after birth due to 
dehydration (Mills, Zheng et al. 1999, Yang, Schweitzer et al. 1999). The DNp63a isoform is the 
most abundantly expressed and physiologically relevant isoform. It is expressed in the basal layer 
of the epidermis where it functions to maintain epithelial stemness (Pellegrini, Dellambra et al. 
2001, Koster and Roop 2004). As keratinocytes differentiate into the upper levels of the epidermis,  
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Figure 1: p63 isoforms. Schematic of the p63 gene comprising of the two promoter sites, 3’ 
splicing segments, and the resulting six main p63 isoforms. The domains are as follows: 
transactivation domain (TA), DNA-binding domain (DBD), oligomerization domain (OD), 
sterile alpha motif (SAM), and transactivation inhibitory domain (TI).   
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cells lose their proliferative capacity as a result of a decrease in DNp63a expression levels (Koster 
and Roop 2004) (Fig. 2).  
 
B. DNp63a and Non-melanoma skin cancer 
  There are approximately 5 million new cases of non-melanoma skin cancer (NMSC) each 
year (Rogers, Weinstock et al. 2015). The two main types are basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). BCC occurs in the basal layer of the epidermis and rarely 
metastasizes, whereas SCC occurs in the squamous cell keratinocytes of the outer layers of the 
epidermis with the potential to metastasize (Safai and Good 1977). One of the main hallmarks of 
these cancers is an increased expression of the proto-oncogene, DNp63a (Reis-Filho, Torio et al. 
2002, Lo Muzio, Santarelli et al. 2005, Bircan, Candir et al. 2006). Numerous studies have 
implicated DNp63a in promoting tumorigenesis via enhanced AKT activation through inhibiting 
transcription of PTEN and positively regulating epidermal growth factor receptor leading to an 
increase in pancreatic cancer cell proliferation (Danilov, Neupane et al. 2011, Leonard, 
Kommagani et al. 2011). Interestingly, loss of DNp63a has shown to promote cancer progression 
in prostate, bladder, and breast cancer as well as increased motility and cell invasion indicating 
that p63 has a complex role in mediating cancer progression (Di Como, Urist et al. 2002, Medina-
Franco, Vasconez et al. 2002, Senoo, Matsumura et al. 2002, Urist, Di Como et al. 2002, Barbieri, 
Tang et al. 2006, Carroll, Carroll et al. 2006, Kommagani, Leonard et al. 2009).  
The primary cause of NMSC is thought to be excessive exposure to ultraviolet (UV) 
radiation, a form of genotoxic stress that can cause DNA lesions, such as cyclobutane pyrimidine 
dimers and 6,4-photoproducts (Boukamp 2005). UV-induced lesions result in programmed cell 
death mediated by c-Jun N-terminal kinase (JNK) and p38 pathways (Zhang and Bowden 2012).  
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Figure 2: Diagram of epidermal stratification. The epidermis consists of four layers starting 
with the basal layer, where ΔNp63α is highly expressed, to the terminally differentiated 
corneum layer. ΔNp63α levels decrease as the keratinocytes differentiate into the upper layers 
of the epidermis. 
	
5	
Furthermore, for apoptosis to occur in keratinocytes, UV-mediated down-regulation of DNp63a is 
required (Liefer, Koster et al. 2000). However, this is not the case as DNp63a is overexpressed in 
NMSC, suggesting that normal apoptotic factors are being inhibited.  
 
C. DNp63a and phosphorylation 
 p63 is phosphorylated following UV treatment, as evidenced by an electrophoretic mobility 
shift in DNp63a and ablated by treatment with alkaline phosphatase (Westfall, Joyner et al. 2005). 
While phosphorylation of TAp63 proteins result in their accumulation, studies have demonstrated 
that phosphorylated DNp63a is ubiquitinated and degraded in a proteasome dependent mechanism, 
leading to programmed cell death, such as phosphorylation of p63 by Dlx3 during development, 
HIPK2 in response to genotoxic drugs, or ALK5 in response to UV (Katoh, Aisaki et al. 2000, 
Okada, Osada et al. 2002, Papoutsaki, Moretti et al. 2005, Westfall, Joyner et al. 2005, Di 
Costanzo, Festa et al. 2009, Lazzari, Prodosmo et al. 2011). In contrast, c-Abl tyrosine kinase can 
phosphorylate tyrosine residues on ΔNp63α inducing its association with Yes-Associated Protein 
(YAP), leading to increased ΔNp63α stability, cell proliferation, and protection from cisplatin-
induced cell death, thus suggesting that the site of phosphorylation on DNp63a may dictate its 
resulting stability and function (Yuan, Luong et al. 2010).  
Previous studies have shown that cellular stress resulted in the activation of the p38 
pathway, leading to the phosphorylation of DNp63a. UV-induced lesions in normal keratinocytes 
induce apoptosis mediated by the p38 pathway (Raingeaud, Gupta et al. 1995). Our laboratory has 
also shown that low doses of Vitamin D3 led to an increase in DNp63a protein levels and 
keratinocyte proliferation via activation of p38 and Akt (Hill, Zhang et al. 2015). Furthermore, 
inhibition of p38 has been shown to repress the electrophoretic mobility shift observed in DNp63a 
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following UV irradiation, while cells overexpressing constitutively active upstream kinases of p38 
show an enhanced mobility shift (Papoutsaki, Moretti et al. 2005). 
 UV-treated keratinocytes also show an increase in activated JNK levels, leading to 
apoptosis (Hibi, Lin et al. 1993, Derijard, Hibi et al. 1994). Although phosphorylation of DNp63a 
by p38 has been documented, a related stress-activated kinase, JNK, has not been eliminated as a 
candidate kinase of DNp63a (Papoutsaki, Moretti et al. 2005). 
 
D. JNK 
 JNK, a stress activated protein kinase (SAPK), is encoded by three different genes (JNK1-
3) that may be differentially spliced to produce at least 10 different isoforms (Zhang and Selim 
2012). JNK signaling is implicated in a wide range of cellular processes such as cell survival, 
proliferation, differentiation, and apoptosis (Hu, Qiu et al. 1997, Buschmann, Potapova et al. 2001, 
Wu 2004, Bode and Dong 2007, Zhang and Selim 2012). JNK1 acts as a tumor suppressor while 
JNK2 is a potent tumor promoter found to be overexpressed in conjunction with its downstream 
substrate, c-Jun, in squamous cell carcinoma, basal cell carcinoma, and melanoma (Hochedlinger, 
Wagner et al. 2002, Sabapathy, Hochedlinger et al. 2004, Bode and Dong 2007, Zhang and 
Bowden 2012). Active JNK is known to directly phosphorylate p53 in response to cellular stress 
and DNA damage, stabilizing protein levels while decreasing ubiquitination and increasing 
transcriptional activity (Hu, Qiu et al. 1997, Fuchs, Adler et al. 1998, Buschmann, Potapova et al. 
2001, Wu 2004, Park, Kim et al. 2016). Phosphorylation of p53 at serine-34 and threonine-81 has 
shown to upregulate p53 transcriptional activity correlating with increased cell cycle arrest and 
induction of apoptosis, respectively (Hu, Qiu et al. 1997, Buschmann, Potapova et al. 2001). 
Studies have shown JNK to be required for p73-mediated apoptosis. JNK phosphorylates p73 on 
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at least seven different residues located in both the N-terminus and C-terminus where phospho-
deficient mutations of these sites prevent p73-mediated apoptosis. These sites are highly conserved 
in DNp63a (Jones, Dickman et al. 2007). Although DNp63a shares conserved residues with other 
known JNK targets in the p53-family of proteins, JNK-mediated phosphorylation of DNp63a has 
not been reported. 
 
E. Downstream targets of ΔNp63α: miRNAs 
 microRNAs (miRNAs) are small non-coding RNAs (approximately 18-22 nucleotides in 
length) that post-transcriptionally regulate gene expression. They are able to bind to 3’ UTR 
regions of target mRNA and translationally repress or degrade them (Lewis, Burge et al. 2005). 
They can also interact with the protein coding regions of mRNA (Helwak, Kudla et al. 2013). 
miRNAs are derived from intragenic regions of the genome as well as introns of pre-mRNAs and 
undergo two processing steps involving ribonucleases to produce mature miRNAs. Initially, a long 
primary transcript (pri-miR) is transcribed by RNA polymerase II and in some cases RNA 
polymerase III, resulting in a stem-loop structure with a 5’ cap and 3’ poly-A tail (Bartel 2004, 
Lee, Kim et al. 2004, Borchert, Lanier et al. 2006). pri-miRNAs are modified by the Drosha 
complex (an RNase III enzyme in complex with DGCR8 and several auxiliary factors) to produce 
hairpin structured precursor miRNAs (pre-miRNAs), which are approximately 70 nucleotides in 
length. pre-miRNAs are transported out of the nucleus via Exportin-5 (XPO5) and Ran-GTP (Zeng 
and Cullen 2004). In the cytoplasm, pre-miRNAs are processed by Dicer, another RNase III 
enzyme, to form mature duplex miRNAs. One of the strands of the miRNA duplex is loaded onto 
the RNA-induced silencing complex (RISC), which contains Argonaute (Ago), and serves as a 
guide to direct RISC to target mRNAs and either degrade, destabilize, or translationally inhibit 
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their expression (Bartel 2009, Jansson and Lund 2012). A single miRNA may target hundreds of 
genes and a single mRNA may be targeted by hundreds of miRNAs, thus the dysregulation of 
several miRNAs can have strong biological effects on entire gene networks. miRNAs may regulate 
key components of various cellular processes such as proliferation, differentiation, apoptosis, 
motility & invasion, morphogenesis, and survival as it is estimated that they may regulate over a 
third of all mammalian genes (Lewis, Burge et al. 2005, Irani 2016). miRNA have been used as 
novel biomarkers for cancer diagnosis. Understanding miRNA expression profiles for various 
cancers has helped to better classify poorly differentiated tumors (Lu, Getz et al. 2005, Wojcicka, 
Kolanowska et al. 2016).  
 
F. ΔNp63α regulation of miRNAs 
 ΔNp63α has been shown to modulate the expression of miRNAs which can have profound 
effects on a number of cellular processes such as regulation of keratinocyte differentiation, cell 
migration, tumor growth, cell cycle arrest, apoptosis, and metabolism just to name a few 
(Ratovitski 2013, Lin, Li et al. 2015, Rodriguez Calleja, Jacques et al. 2016). Whereas ΔNp63α 
can transcriptionally activate a number of miRNAs, it also plays a role in the post-transcriptional 
processing of miRNAs specifically by acting on the Drosha complex and Dicer. It’s been shown 
that ΔNp63α transcriptionally activates DGCR8 in the Drosha complex and could possibly interact 
with it through a PY-WW domain interaction (Chakravarti, Su et al. 2014). Furthermore, ΔNp63α 
regulates other transcription factors that regulate miRNAs. For example, Runt-related transcription 
factor 1, (RUNX1) which regulates miR-424, was identified as a target of ΔNp63α (Ortt, Raveh 
et al. 2008, Masse, Barbollat-Boutrand et al. 2012). It is clear that ΔNp63α regulates miRNAs 
directly and indirectly and the resulting regulatory network implicates it in a variety of cellular 
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processes. We set out to elucidate the global regulation of miRNAs by ΔNp63α by obtaining a 
ΔNp63α regulated miRNA expression profile via small RNA-Seq. 
 
G. small-RNA Seq and data processing workflow 
In recent years, improvements in next-generation sequencing (NGS) technology has made 
small RNA-Seq possible – a high throughput technology that queries small RNA species such as 
miRNAs with unprecedented sensitivity and dynamic range. Small RNA-Seq is increasingly being 
used for the comprehensive profiling of miRNAs for the purposes of classifying and categorizing 
diseases such as cancer and their prognoses (Lin, Lin et al. 2014, Alisoltani, Fallahi et al. 2015, 
Kou, Qiao et al. 2015). Despite the increasing popularity of small RNA-Seq, there is no consensus 
on an optimized data processing pipeline for miRNA sequencing data. The general processing for 
any sequencing experiment consists of mapping the sequenced reads to a reference genome, 
quantifying the abundance of each feature into raw read counts, and normalizing the raw read 
counts for subsequent downstream analyses, such as differential expression analysis (Conesa, 
Madrigal et al. 2016). However, the effect of available options at each stage of processing have 
not been fully explored for processing miRNA sequencing data despite the fact that parameters at 
each step of the processing can have a strong impact on the downstream analysis and classification 
of significantly differentially expressed (DE) miRNAs. Thus, I sought to develop an optimized 
pipeline workflow suitable for the identification of DE miRNAs. 
In addition to optimizing a pipeline for small RNA-Seq, I sought to further elucidate 
ΔNp63α’s function in epithelial tissues by identifying novel ΔNp63α-regulated miRNAs. Using 
the optimized pipeline, I selected several miRNAs that were significantly differentially expressed 
by small RNA-Seq and which had no known link to ΔNp63α and validated them using quantitative 
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real-time PCR, which is considered the gold standard for confirming next-generation sequencing 
experiments. Validation of several miRNAs in addition to having a significant DE list that was 
enriched for previously identified ΔNp63α-regulated miRNAs suggested that the pipeline was 
robust for the practical analysis of small RNA-Seq to identify differentially expressed miRNAs by 
a given transcription factor. 
 
H. Rationale:  
 ΔNp63α is essential for the maintenance of epithelial tissue integrity, but its role in UV-
induced damage and other forms of cellular stress remain poorly defined. As well, being a proto-
oncogene, it plays a role in various cellular processes that influences the progression of numerous 
cancers, yet its regulatory network has not been fully investigated.  
 ΔNp63α activity and turnover appear to be regulated post-transcriptionally, and post-
translational modifications may dictate the functional contribution of ΔNp63α in response to 
cellular stress. I showed herein that both endogenous and exogenous JNK induced an 
electrophoretic mobility shift in ΔNp63α in response to UV or Anisomycin treatment due to 
phosphorylation at multiple ΔNp63α residues. JNK-mediated phosphorylation occurred rapidly, 
within 30 minutes of the aforementioned cellular stress, and preceded ΔNp63α protein 
degradation, thus suggesting that phosphorylation of ΔNp63α by JNK may be an immediate early 
driver of ΔNp63α degradation and apoptotic progression. 
 Likewise, to further elucidate ΔNp63α’s regulatory network within epithelial tissues, I 
assessed the global miRNA expression profile within keratinocytes as regulated by ΔNp63α via 
small RNA-Seq. I optimized critical data-mining parameters for assessing miRNA sequencing data 
and performed differential expression analysis to identify miRNAs that were significantly 
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differentially expressed. This methodology afforded critical insights into the predicted 
downstream targets of ΔNp63α and suggested that ΔNp63α may regulate a number of pathways 
that mediate cancer progression. Validation of several miRNAs with no previous connection to 
ΔNp63α may provide critical information concerning ΔNp63α’s role in maintaining epidermal 
integrity as well as determining tumorigenic fate. 
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II. MATERIALS AND METHODS 
A. Cell culture, reagents, and plasmids 
HaCaT, a non-tumorigenic immortalized human keratinocyte cell line, was obtained from 
Dr. Nancy Bigley (Wright State University). H1299, a human non-small cell lung carcinoma cell 
line, which is null for p63 was used for overexpression studies. Both cell lines were maintained 
using DMEM Hyclone media supplemented with 8% fetal bovine serum and 100U/mL penicillin 
and streptomycin (referred to as complete media) at 37oC in 5% CO2. UVC treatments were carried 
out using the UV Stratalinker 1800. Anisomycin was prepared in DMSO as 1 mg/ml stock solution.  
Expression plasmids encoding DNp63a were made as described previously (Kommagani, 
Leonard et al. 2009). Expression plasmids encoding HA tagged JNK1 and HA tagged JNK2 were 
a kind gift from Dr. Anja Jaeschke at University of Cincinnati. Expression plasmids encoding 
single site phospho-deficient mutants of DNp63a (S53A, S66A, S369A, T397A, and T444A) were 
constructed by Genscript services. Expression plasmid encoding a multi-site phospho-deficient 
mutant of DNp63a (S53, S66, S361, S369, T288, T397, and T444) was constructed by Genscript 
services.  
 
B. Transient transfections  
Cells were seeded at 3.5 x 105 into 6 well plates or 1.0 x 106 into 6 cm cell culture dishes 
prior to the day of transfection. At approximately 75% cell confluency, transient transfections were 
performed using Lipofectamine 2000 (ThermoFisher Scientific, Carlsbad, CA, USA) with desired 
plasmids (1:2 DNA to Lipofectamine 2000) in Opti-MEM solution as previously described 
(Leonard, 2011). After 5 to 6 hours of incubation at 37°C, media was replaced with fresh complete 
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media. For all studies, a total of 2 µg (6 well plate) or 3 µg (6 cm cell culture dish) of desired 
expression plasmids were used, adjusted for quantity using an empty vector plasmid.  
 
C. Immunoblot analysis  
At the time of harvest, cells were washed with cold PBS and whole cell extracts were made 
by lysing the cells in a buffer containing the phosphatase inhibitor buffer (50mM Tris-HCl pH 8.0, 
120 mM NaCl, 5 mM EGTA, 1 mM EDTA, 5 mM NaPP, 10 mM NAF, 30 mM PMSF, 0.2 mM 
PMSF, 1 mM Benzamidine, 0.1% NP-40, 100 nM NaVO4) supplemented with protease inhibitor 
cocktail (catalog #P8340, Sigma-Aldrich, St. Louis, MO). Protein concentration was quantitated 
using Bicinichoninic acid assay (BCA) according to the manufacturer’s instructions 
(ThermoFisher Scientific, Fremont, CA, USA). Equivalent amounts of protein were separated on 
7.5% or 10% SDS-PAGE and transferred to PVDF membrane at 350 mA for 1 hour. Proteins were 
detected using the following antibodies: Mouse monoclonal anti-phospho-JNK (T183/Y185, 
1:2,000, Cell Signaling), rabbit polyclonal anti-JNK (#9652, 1:1,000, Cell Signaling), rabbit 
polyclonal anti-phospho-cJun (S63, 1:1,000, Cell Signaling), rabbit polyclonal anti-p63 (N2C1, 
1:2,000, GeneTex), mouse monoclonal anti-pan-p63 (4A4, 1:10,000, Cell Signaling), and 
monoclonal anti-β-actin (AC15, 1:10,000, Santa Cruz) antibodies were used to detect phospho-
JNK, JNK, phospho-c-Jun, ΔNp63α, and β-actin, respectively. Appropriate horseradish 
peroxidase antibodies (Promega, Madison, WI, USA) were used as secondary antibodies for 
chemiluminescent detection with the Western Lightning Plus-ECL Chemiluminescent Substrate 
kit (Perkin Elmer, Waltham, MA). 
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D. Immunoprecipitation and Mass spectrometry 
H1299 cells were plated in 6 cm dishes transfected with myc-tagged ΔNp63α and exposed 
to UVC or Anisomycin treatment as described. Protein extracts were obtained by lysing cells with 
p40 lysis buffer (1% IGEPAL, 150mM NaCl, 1mM DTT, 25mM Tris pH 7.39, 1% Na3VO4, 
2.5mM NaF, 0.5mM Sodium Pyrophosphate) supplemented with protease inhibitor cocktail 
(catalog #P8340, Sigma-Aldrich, St. Louis, MO). Samples were pre-cleared with Protein A 
agarose beads (Santa Cruz) and rotated overnight at 4oC with mouse monoclonal anti-myc-tag 
(9B11, 1:1000, Cell Signaling) or mouse monoclonal anti-p63 (4A4, 1:1000, Abcam) antibody. 
Protein was immunoprecipated using Protein A agarose beads and samples were separated via 
SDS-PAGE in duplicate for immunoblot analysis and Coomassie blue staining. Protein bands 
identified by immunoblot were excised from the Coomassie gel and assessed for post-translational 
modifications by mass spectrometry. 
 
E. in vitro Kinase Assay 
 Recombinant active JNK1 with N-terminal His-tag (1 µl of 50 ng/µl working stock) (#14-
327, EMD Millipore), recombinant active JNK2 with N-terminal His-tag (1 µl of 50 ng/µl working 
stock) (#14-329, EMD Millipore), and recombinant DNp63a (1 µg) proteins were incubated in a 
30 µl reaction consisting of 3 µl of 10X Reaction buffer (500 mM Tris/HCl (pH 7.5), 1mM EGTA, 
5mM DTT, 200 mM MgCl2, 75 mM 2-glycerophosphate) and 50 µM 32P g-labeled ATP (2.5 
µCi/reaction) or non-labeled ATP (for purposes of mass spectrometry) at 30°C for 30 min (brought 
up to 30 µl in sterile distilled water). Similar reactions were performed using recombinant active 
c-Jun (1-79) activation domain fused to GST (#420108, Calbiochem) as a positive control. 7 µl of 
5X sample buffer were added to samples after the reaction, boiled at 95°C for 5 min, and the 
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proteins were resolved via SDS-PAGE. Gels were stained using Coomassie blue to visualize 
protein bands. Then, the gels were de-stained, let dry, and phosphorylation was detected via 
autoradiography.  
 
F. siRNA Knockdown 
Knockdown of p63 in HaCaT cells was performed following transfection with either 
siRNA against p63 (sip63) or non-silencing control (NSC) using Lipofectamine RNAi-Max as per 
the manufacturer’s instructions (ThermoFisher Scientific, Carlsbad, CA, USA). The siRNA 
against p63 used in this study was purchased from Qiagen (Valencia, CA, USA) as previously 
described (Kommagani, Leonard et al. 2009, Clarke, Newman et al. 2015).  
 
G. qRT-PCR - silencing confirmation and small-RNAseq validation  
Total RNA was extracted from HaCaT cells transfected with siRNA against p63 (sip63) 
and non-silencing control (NSC) using the mirVanaTM ParisTM Isolation kit according to the 
manufacturer’s protocol (ThermoFisher Scientific, Carlsbad, CA, USA). 1 µg of total RNA input 
was used for cDNA synthesis using a TaqMan reverse transcription kit (ThermoFisher Scientific, 
Carlsbad, CA, USA). TaqMan based quantitative real-time PCR analysis was performed as 
previously described (Kommagani, Leonard et al. 2009). Assays on Demand (AODs) for p63 
(Hs00978340_ml), normalized to GAPDH (4325792) (ThermoFisher Scientific, Carlsbad, CA, 
USA), were used. For miRNA RT-PCR, cDNA was synthesized from 10 ng of total RNA. 
Quantitative real-time PCR analysis was performed using the QuantStudio 7 Flex Real-Time PCR 
System using TaqMan 2× master mix and miRNA-specific AODs for hsa-miR-103a-3p (00439), 
hsa-miR-149-5p (002255), hsa-miR-18a-5p (002422), hsa-miR590-5p (001984), hsa-miR-7-5p 
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(000268), hsa-miR-708-5p (002341), hsa-miR-744-5p (002324), hsa-miR-93-5p (001090) 
normalized to RNU48 (001006) (ThermoFisher Scientific, Carlsbad, CA, USA). qRT-PCR was 
done in triplicate for each specific miRNA of interest for each sample and performed using 3 
biological replicates of NSC and sip63 transfected HaCaT cells. 
 
H. small RNA-Seq library preparation 
 Total RNA was isolated from HaCaT cells using the mirVanaTM Paris kit and enriched for 
small RNA through size selection ethanol washes. For each library, 4 ng of small RNA was ligated 
to adapters containing a unique barcode (Ion Xpress RNA-Seq Barcode 1-16 Kit, ThermoFisher 
Scientific, Carlsbad, CA, USA). Small RNA samples were reverse transcribed to cDNA using 
adapter specific primers (Ion Total RNA-Seq kit v2.0, ThermoFisher Scientific, Carlsbad, CA, 
USA). cDNA samples were size-selected and amplified followed up by a clean-up step using 
nucleic acid magnetic beads (ThermoFisher Scientific, Carlsbad, CA, USA). cDNA samples were 
barcoded using Platinum PCR SuperMix High Fidelity polymerase with IonXpress RNA 3’ 
Barcode primer and unique 5’ Ion Xpress RNA-Seq Barcode Primers (reduced to 0.5 µl each) (Cat 
#4471250, Ion Xpress RNA-Seq Barcode 1-16 Kit, ThermoFisher Scientific, Carlsbad, CA, USA). 
The yield and size distribution of the cDNA libraries were assessed using the Agilent 2100 
Bioanalyzer using the High sensitivity DNA chip (DNA1000 chip, #5067-1504, Agilent 
Technologies, Santa Clara, CA, USA). Total cDNA within the 50-300bp range is considered to be 
obtained from small RNA. Of particular interest, the 94-114bp range is considered cDNA library 
from miRNA. 7.5 picomoles of each barcoded library were pooled and clonally amplified onto Ion 
SphereTM Particles (ISPs) per the manufacturer’s protocol (Ion OneTouchTM 200 Template Kit v2 
DL kit) and enriched using the Ion OneTouch 2 ES system (ThermoFisher Scientific, Carlsbad, 
	
17	
CA, USA). Enriched ISPs were sequenced on the Ion Proton Next Generation Sequencing system 
using Ion P1 chip and Ion Total RNA Seq Kit v2 (ThermoFisher Scientific, Carlsbad, CA, USA) 
with 500 sequencing flows. 
 
I. small RNA-Seq data analysis 
Alignment and Quantification: Sequenced reads were assigned to their respective samples 
based on corresponding IonXpress barcodes and output in FASTQ format with corresponding base 
quality scores using the Ion Torrent software. FASTQ files were uploaded into Partek Flow (Partek 
Inc., St. Louis, MO, USA) for processing. Reads were initially trimmed on both ends based on a 
minimum Phred quality score of 20 and a minimum read length greater than 15 nucleotides after 
trimming (The default minimum read length is 25 nucleotides). High quality trimmed reads were 
mapped using three reference genomes (whole genome, RefSeq Transcripts v2 (05-02-2016), and 
miRBase mature miRNAs version 21) of the latest human genome assembly, hg38, using the 
Bowtie aligner, an ultrafast, memory-efficient alignment algorithm that aligns short DNA 
sequence reads to large genomes with a seed mismatch limit of 1 and minimum seed length of 10. 
At the command line, the bowtie options would be entered as such: bowtie –n 1 –l 10 (Langmead, 
Trapnell et al. 2009). To obtain raw read counts, uniquely mapped reads were quantified to 
miRBase version 21 using an Expectation Maximization (EM) algorithm (Do and Batzoglou 
2008). EM is a process that resolves ambiguous mappings (i.e., if a read can align equally well to 
multiple transcripts) to best estimate true expression read counts for a sample. It does so by starting 
with an initial estimate of transcript abundance (uniquely mapped reads) and calculates weighted 
means of ambiguous reads. The weighted means are used to re-compute the global transcript 
abundances which are then used to re-compute newly weighted means. This process is iterated 
	
18	
until it converges, at which point the reads assigned to a particular locus are counted resulting in 
the raw read counts (Do and Batzoglou 2008).  
Normalization: Raw read counts were normalized to account for differences in library sizes 
and coverage. Several normalization methods were evaluated, including (1) Total Count (TC) 
(Dillies, Rau et al. 2013), (2) Reads Per Kilobase per Million (RPKM) (Mortazavi, Williams et al. 
2008), (3) Transcripts Per Million (TPM) (Li, Shen et al. 2009, Li and Dewey 2011), and (4) 
Trimmed Mean of M values (TMM) (Robinson and Oshlack 2010). All normalization methods 
included an offset value of 1. (A miRNA with 0 counts would otherwise affect statistical 
calculations when performing differential expression analysis). 
Differential Expression (DE) Analysis: The model design for DE analysis was selected 
based on our experimental design which compared the three p63 silenced biological replicates 
(sip63) to the three non-silenced control replicates (NSC). We tested two response distribution 
approaches: (1) The multimodel approach, which fit the normalized reads for each miRNA to the 
best model type (normal, negative binomial, lognormal, or lognormal with shrinkage) based on the 
model which had the lowest Akaike information criterion and (2) the lognormal with shrinkage 
(LNS) approach, similar to the “limma-trend” implemented in the limma package (Law, Chen et 
al. 2014). The shrinkage factor accounts for gene-specific dispersion, improving reproducibility in 
a low replicate study. A low expression threshold filter is applied to filter out the proportion of 
miRNAs that have 0 read counts as they are not of interest in the study and would otherwise affect 
the overall estimated trend of dispersion and shrinkage of error terms, resulting in an inaccurate 
model. As well, these miRNAs cannot be modeled well by a continuous distribution such as 
lognormal. Each approach generated statistical values such as p-value using the F statistic.  
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Principal Components Analysis (PCA): PCA is an exploratory data technique that reduces 
the dimensionality of a dataset by creating synthetic variables known as principal components (PC) 
that summarize the variance in the original data. The first PC is calculated such that it captures the 
largest portion of variance. The second PC is orthogonal to the first and captures the largest portion 
of the remaining variance. Each new PC is orthogonal to its preceding PCs and captures the largest 
portion of the remaining variance. Typically, only the first two or three PC dimensions are 
displayed in a figure as they sufficiently represent much of the variation within the entire dataset. 
In order to assess the clustering of biological replicates for each of the chosen normalization 
methods, PCA was performed on each of the normalized read datasets using Partek Flow (Partek 
Inc., St. Louis, MO, USA). Data was presented in two PC dimensions for ease of comparison 
between normalization methods.  
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III. RESULTS 
 
 In the following section, results are presented as upstream regulation of DNp63a by JNK 
(Section III.A) and the development and optimization of a suitable pipeline analysis for miRNA 
sequencing data to identify novel DNp63a-regulated miRNAs and pathways they affect (Section 
III.B). 
 
A. Regulation of DNp63a by JNK kinase. 
i. UVC and Anisomycin mediated JNK activation correlate with a DNp63a mobility shift 
HaCaT cells were treated with either UVC (150 J/m2) or Anisomycin (1 µg/ml), both potent 
inducers of stress activated protein kinases to confirm JNK activation. Cells were harvested at 
various time-points post treatment: 30 min, 1 hr, 2 hrs, and 4 hrs. Treatment with either UVC or 
Anisomycin led to a potent activation of JNK within 30 minutes of treatment (Fig. 3A, B). cJun, 
a downstream target of JNK, was also phosphorylated upon JNK activation within 30 minutes of 
treatment, serving as a positive control for JNK’s kinase activity (Fig. 3A, B). Interestingly, we 
observed an electrophoretic mobility shift in the ΔNp63α specific band upon JNK activation as 
early as 30 min following UVC (Fig. 3A) and Anisomycin (Fig. 3B) treatment. This shift 
continued to increase through the 4-hour treatment. Our finding of UVC or Anisomycin induced 
electrophoretic mobility shift in ΔNp63α correlates with JNK activation, suggesting that JNK is 
likely responsible for the phosphorylation of ΔNp63α.  
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Figure 3: UVC and Anisomycin-induced JNK activation corresponds to an 
electrophoretic mobility shift in DNp63a.  (A) HaCaT cells were treated with UVC (150 J/m2) 
or (B) Anisomycin (1 µg/ml) or an equivalent volume of DMSO. Cells were harvested at 
various time-points post treatment and whole cell extracts were obtained. Protein extracts were 
subjected to immunoblot analysis for the phospho-JNK (pJNK), JNK, DNp63a, phospho-cJun 
(p-cJun), and b-actin. β-actin was included as a loading control to show an equivalent amount 
of protein was added in each lane. 
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ii. Co-Expression of ΔNp63α and JNK1/2 enhances the ΔNp63α mobility shift 
We overexpressed ΔNp63α plasmid alone or with HA tagged JNK1 or JNK2 plasmid in 
H1299 cells, a non-small cell lung carcinoma cell line which is null for p53 and does not express 
p63. In the absence of UVC treatment, co-expression of JNK1 or JNK2 with ΔNp63α did not lead 
to a ΔNp63α electrophoretic mobility shift (Fig. 4). As expected, UVC treatment led to JNK 
activation when compared to untreated cells (Fig. 4), (compare lanes 9 – 12 to lanes 3 – 6) which 
corresponded to phosphorylation of its downstream target, c-Jun. Consistent with Figure 1, JNK 
activation corresponded to an electrophoretic mobility shift in ΔNp63α (Fig. 4, lanes 9 & 10) 
when compared to untreated cells (Fig. 4, lanes 3 & 4). These data are consistent with our 
hypothesis that JNK phosphorylates ΔNp63α. 
 
iii. in Vitro Kinase Assay confirms that JNK directly phosphorylates ΔNp63α  
 In order to confirm that JNK1 and JNK2 are directly involved in the phosphorylation of 
ΔNp63α, an in vitro kinase assay was performed using recombinant ΔNp63α alone as a control 
or along with recombinant active JNK1 or JNK2 using 32P g-labeled ATP.  In the Coomassie stain 
shown in Figure 5, the upper band represents the recombinant ΔNp63α and the lower band 
represents cleaved GST (residual contamination from the recombinant ΔNp63α protein 
purification). An autoradiograph of the dried gel clearly demonstrates that JNK1 and, to a lesser 
extent, JNK2 directly phosphorylate ΔNp63α. The lack of a GST tag band on the autoradiograph 
(Fig. 5, right panel) serves as an internal control indicating that phosphorylation of ΔNp63α by 
JNK1 and JNK2 was specific. Taken together, these results strongly suggest that JNK 
phosphorylates ΔNp63α as indicated by the mobility shift observed in Figures 1 and 2.  
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Figure 4: Co-expression of JNK and ΔNp63α leads to an enhanced mobility shift in ΔNp63α. 
H1299 cells were transfected with plasmids encoding either empty vector (EV), ΔNp63α (p63), 
HA-tagged JNK1, or HA-tagged JNK2 as indicated. Cells were treated with UVC (150 J/m2) 24 
hours post transfection and incubated in normal complete growth media for 2 hours following 
UVC treatment. Whole cell extracts were obtained. Protein extracts were subjected to immunoblot 
analysis for phospho-JNK (pJNK), JNK, ΔNp63α, phospho-cJun (p-cJun), and β-actin. β-actin 
was included as a loading control to show an equivalent amount of protein was added in each lane. 
Lane	
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Figure 5: JNK phosphorylates DNp63a in vitro. Recombinant DNp63a and recombinant 
active JNK1 or JNK2 were incubated together in an in vitro kinase assay using 32P g-labeled 
ATP and subjected to SDS-PAGE. Recombinant proteins were Coomassie stained (Left) and 
analyzed for radiolabeled phosphorylation as shown in the autoradiograph (Right). Performed 
with the help of Dr. Weiwen Long at Wright State University. 
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iv. ΔNp63α is phosphorylated on conserved JNK-targeted residues 
 p63 is homologous to its family members p53 and p73 (Yang, Kaghad et al. 2002). 
Previously, p73 has been shown to be phosphorylated by JNK (Jones, 2007). As shown in Figure 
6, both the JNK binding site as well as the p73 residues phosphorylated by JNK are highly 
conserved in human and mouse p63. It is known that ΔNp63α is phosphorylated in vivo by p38 in 
response to UV irradiation, while the ΔNp63γ isoform of p63 which lacks the C-terminal SAM 
and TID domains is not, suggesting that the region targeted by p38 lies within exons 11 and 12, 
specifically between amino acid residues 357 and 457 of ΔNp63α (Papoutsaki, Moretti et al. 2005). 
These are different from the predicted JNK target sites. 
In order to identify potential JNK phosphorylation sites on ΔNp63α, whole cell extracts 
from UVC-treated H1299 cells expressing ΔNp63α were subjected to immunoprecipitation (IP) 
using a p63 specific antibody and subjected to SDS-PAGE analysis followed by Coomassie 
staining and immunoblot analysis. Recombinant GST-cleaved ΔNp63α was used as a marker for 
the immunoprecipitated ΔNp63α (approximately 72 kDa) (Fig. 7A). Immunoblot analysis 
confirmed an electrophoretic mobility shift in ΔNp63α (Fig. 7B). The ΔNp63α band was excised 
and subjected to mass spectrometry analysis. Post-translational modifications on ΔNp63α 
following UVC treatment were detected, revealing phosphorylation of multiple residues, three of 
which are conserved between p63 and p73 (Fig 7C, D). 
 
v. Site directed mutagenesis of ΔNp63α 
 The mass spectrometry data along with the conservation of potential JNK phosphorylation 
residues, identified by comparison to p73, led us to focus on several residues as potential JNK  
 
	
26	
 
 
 
 
 
 
 
  
Figure 6: ΔNp63α contains putative JNK phosphorylation sites. JNK phosphorylation and 
interaction sites are conserved between p63 and p73. Aligned amino acid sequences of human and 
mouse ΔNp63α with human TAp73 are shown with the JNK interaction sequence (underlined) and 
putative phosphorylation sites, with the neighboring proline, in bold. 
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Figure 7: Mass spectrometry data reveals potential sites of phosphorylation on ΔNp63α. 
H1299 cells were transfected with plasmid encoding ΔNp63α, treated with 150 J/m2 UVC and 
maintained in complete media for 2 hours. Cells were harvested and subjected to 
immunoprecipitation with a pan-p63 antibody. Immunoprecipitated protein was subjected to 
(A) Coomassie stain and (B) immunoblot analysis to detect ΔNp63α. (C) The ΔNp63α band 
was excised from the Coomassie stained gel and subjected to mass spectrometry analysis to 
detect post-translational modifications. Phosphorylated residues are indicated as “P” with 
shading indicative of PTM site probability. (D) Phosphorylated ΔNp63α residues identified by 
mass spectrophotometry and homology to TAp73α are listed. 
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phosphorylation sites within ΔNp63α. To identify the significance of each of these potential sites, 
single phospho-deficient site mutants were constructed at S53, S66, S369, T397, and T444 by 
mutating the wild type residues into an alanine (Table 1). We examined whether these sites are 
required for the phosphorylation of ΔNp63α by UV-activated JNK. H1299 cells were transfected 
with wild type ΔNp63α or the single phospho-deficient site mutants and treated with UVC.  
 UVC treatment resulted in the activation of JNK1 and JNK2 as expected and the 
phosphorylation of its downstream substrate c-Jun (Fig. 8A), consistent with Figures 1 and 2. 
Furthermore, wild-type ΔNp63α exhibited an electrophoretic mobility shift upon UVC treatment 
as expected (Fig. 8A). However, the single phospho-deficient site mutants also exhibited an 
electrophoretic mobility shift similar to that observed in wild-type ΔNp63α following UVC 
treatment (Fig. 8A), suggesting loss of any of the single phosphorylation sites was insufficient to 
fully block UVC-mediated phosphorylation of ΔNp63α by JNK. To determine whether the 
electrophoretic mobility shift in exogenously supplied ΔNp63α could be enhanced by increasing 
active JNK levels, H1299 cells were co-transfected with ΔNp63α and HA tagged JNK1 or JNK2 
or the single phospho-deficient site mutants and HA tagged JNK1 or JNK2 followed by UVC 
treatment (Fig. 8B, C). Wild-type ΔNp63α co-expressed with JNK1 and JNK2 exhibited an 
electrophoretic mobility shift upon UVC treatment, as expected (Fig. 8B, C). Similarly, the UVC-
induced electrophoretic mobility shift of the single phospho-deficient site mutants was enhanced 
when overexpressed with JNK1 or JNK2 (Fig. 8B, C). The observation that the electrophoretic 
mobility shift was unchanged in the single phospho-deficient ΔNp63α mutants suggests either that 
multiple residues on ΔNp63α may be phosphorylated by JNK, or that another residue not tested 
is responsible for the observed mobility shift. 
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ΔNp63α 
Position Wild Type Mutant 
53 S A 
66 S A 
369 S A 
397 T A 
444 T A 
Table 1: Site directed mutagenesis of ΔNp63α. Five (S53A, S66A, S369A, T397A, T444A) 
single phospho-deficient mutants of ΔNp63α were synthesized by replacing the wild type 
amino acid residue with an alanine. A multiple phospho-deficient mutant of ΔNp63α (all seven 
amino acid residues mutated) was synthesized by replacing the wild type amino acid residues 
with alanine.  
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Figure 8: Mutation of single phosphorylation sites of ΔNp63α does not prevent its 
mobility shift. (A) H1299 cells were transfected with empty vector, myc-tagged wild type 
ΔNp63α, S53A, S66A, S369A, T397A, and T444A DNp63a mutants. 24 hrs post transfection, 
cells were treated or left untreated with UVC (150 J/m2). Protein lysates were subjected to 
immunoblot analysis. (B) H1299 cells were transfected with empty vector, myc-tagged wild 
type ΔNp63α or a multiple phospho-deficient ΔNp63α mutant. Cells were then treated with 
UVC (150 J/m2) or Anisomycin (1 µg/ml). Protein lysates were subjected to immunoblot 
analysis. β-actin was included as a loading control to show an equivalent amount of protein was 
added in each lane. 
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In order to identify additional candidate phosphorylation sites, an in vitro kinase assay 
using recombinant ΔNp63α in conjunction with recombinant active JNK1 or JNK2 in the presence 
of non-radiolabeled ATP was performed. These samples were subject to mass spectrometry 
analysis to reveal potential sites of phosphorylation (Fig. 9). Specifically, residues T288 and S361, 
were phosphorylated by both JNK1 and JNK2 making them potential sites to consider for 
mutagenesis. 
In order to test the possibility that the observed mobility shift in ΔNp63α was caused by 
concurrent phosphorylation of multiple residues, a phospho-deficient mutant (PD mut) with all the 
site directed mutations identified by mass spectrometry was generated. Residues S53, S66, S361, 
S369, T288, T397, and T444 were mutated to an alanine to prevent phosphorylation at those sites 
and transfected into H1299 cells to test whether the mutant protein exhibited a UV-induced 
electrophoretic mobility shift. As shown previously, UVC treatment led to phosphorylation of c-
Jun, confirming that JNK was activated despite detecting low levels of active JNK. That 
corresponded with a slight mobility shift in wild-type ΔNp63α (Fig. 10). H1299 cells transfected 
with the PD-mut and treated with UVC did result in a slight mobility shift as well. Interestingly, 
there was a significant decrease in protein levels of the wild-type ΔNp63α following UVC or 
Anisomycin treatment consistent with previous reports that phosphorylation of ΔNp63α targets it 
for ubiquitin-mediated degradation (Yang, Kaghad et al. 2002, Di Costanzo, Festa et al. 2009, 
Lazzari, Prodosmo et al. 2011). By contrast, however, the protein levels of the PD-mut remained 
largely unchanged following UVC or Anisomycin treatment compared to the wild-type (Fig. 10). 
This suggests that the mutation of these residues may prevent JNK-mediated phosphorylation and 
prevent tagging for proteasomal degradation, whereas, the wild-type is subject to JNK-mediated 
phosphorylation and subsequent targeting for proteasomal degradation.  
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DNp63a + JNK1 
Position Target Modification Classification 
Highest PTM 
Score 
Highest 
Peptide 
Confidence 
Sequence Motif 
288 T Phospho Post-
translational 
100 High RPFRQNtHGIQMT 
332 Y Phospho Post-
translational 
94.7 High SLELMQyLPQHTI 
361 S Phospho Post-
translational 
65.2 High KQTSIQsPSSYGN 
520 S Phospho Post-
translational 
65.4 High HEFSSPsHLLRTP 
	
DNp63a + JNK2 
Figure 9: Sites on ΔNp63α that are highly phosphorylated in response to JNK.  Sites were 
identified by mass spectrometry following an in vitro kinase assay utilizing non-radiolabeled 
ATP. (Top chart) Sites on ΔNp63α that are phosphorylated by recombinant active JNK 1. 
(Bottom chart) Sites on ΔNp63α that are phosphorylated by recombinant active JNK 2.  
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Figure 10: Site-directed mutagenesis of multiple phospho-residues attenuates protein 
degradation. H1299 cells were transfected with empty vector, myc-tagged wild type 
DNp63a or the multiple phospho-deficient DNp63a mutant (PD mut). Cells were then 
treated with UVC (150 J/m2) or Anisomycin (1 µg/ml). Whole cell extracts were subjected 
to immunoblot analysis. β-actin was included as a loading control to show an equivalent 
amount of protein was added in each lane. 
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B. Identification of ΔNp63α targeted miRNA by small RNA-Seq by establishing an 
optimized small RNA-Seq pipeline 
 
 Currently, there is no consensus on a formal analysis pipeline for analyzing miRNA 
sequencing data. My goal was to develop an optimized pipeline workflow for analyzing miRNA 
sequencing data that would be accurate, stringent, and reliable, thus providing consistent results. 
The various alignment references, normalization methods, and response distribution models 
available for small RNA-Seq data processing affect the number of miRNAs that are classified as 
significantly differentially expressed, making the selection of optimal processing parameters 
critical for accurate miRNA expression profiling and validation (Langmead and Jha 2009, 
Oshlack, Robinson et al. 2010, Ramskold, Kavak et al. 2012, Conesa, Madrigal et al. 2016). I 
tested multiple analysis pipeline configurations including multiple permutations at crucial data 
processing steps while keeping the remaining processing parameters consistent. Figure 11 shows 
an overview of the processing workflows considered in pipeline optimization analysis. 
 
i. Silencing p63  
 HaCaTs, non-tumorigenic keratinocyte cells, were used to study ΔNp63α’s role within 
epithelial tissue. These cells were chosen because they express ΔNp63α, the most physiologically 
relevant isoform of p63 expressed in the basal layer of the skin (Koster, Kim et al. 2004, Koster 
and Roop 2004, Koster and Roop 2004). All three biological replicates of HaCaT cells transfected 
with siRNA against p63 (sip63) showed an 80% reduction in p63 transcript levels (Fig. 12A) and 
no detectable p63 protein (Fig. 12B) relative to the non-silencing control (NSC) (representative 
data shown). 
 
 
	
37	
 
 
 
 
Figure 11: Data processing workflow. Schematic of workflow for evaluating different 
combinations of alignment references and normalization procedures considered in our studies.  
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Figure 12: ΔNp63α is silenced in HaCaT samples used for small RNA-Seq. HaCaT cells 
were transfected with either non-silencing control siRNA or siRNA against p63. A) qRT-PCR 
analysis of p63 transcript levels normalized to endogenous GAPDH. B) p63 protein levels in 
NSC and sip63 cell lysates.  β-actin was included as a loading control to show an equivalent 
amount of protein was added in each lane. Silencing experiments were performed and 
confirmed by Dr. Natasha T. Hill. 
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ii. Qualitative assessment of small RNA-Seq data  
 Unaligned reads were trimmed on both ends prior to the alignment step based on a Phred 
quality score of 20 and a minimum read length of 15 in order to capture the population of miRNAs 
in our samples. Quantitating the aligned reads from the HaCaT study samples yielded a raw read 
count for each miRNA feature in the miRBase database for each sample. I assessed the distribution 
of miRNA read counts obtained by whole genome, RefSeq, and miRBase aligned reads (Fig. 13). 
The distribution of the whole genome or RefSeq Transcripts aligned reads were very similar with 
most of miRNAs having 0 reads, indicating that approximately 85% of miRNA features were not 
quantified after aligning to either reference. By contrast, a majority of miRBase aligned reads had 
miRNAs with counts between 10 and 1,000 reads. Thus, more miRNA features were quantified 
with the aligned reads when miRBase was used as the alignment reference. 
 The quality of read mapping for each alignment was assessed by determining the 
percentage of aligned reads that mapped to actual miRNA sequences. Table 2 summarizes the 
percent match and quantified reads for each of the alignment references. Aligning to whole genome 
and RefSeq Transcripts references yielded on average more mapped reads as compared to aligning 
to miRBase for both sip63 and NSC (Table 2). However, only a small fraction of those aligned 
reads mapped fully within a miRNA and were quantified as such. The opposite was the case with 
miRBase alignment reference. Although only a small percentage of total reads were mapped, 100% 
of the mapped reads were quantified as miRNA counts yielding on average more miRNA counts 
than whole genome and RefSeq Transcript aligned reads. Only 1 alignment was reported per read 
(the first valid alignment Bowtie comes across), suggesting that in aligning to the whole genome 
or RefSeq Transcripts, there was a higher probability for reporting an aligned read  
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Figure 13: Raw read count distributions for each alignment reference. The frequency of raw 
read counts from each of the biological replicates for each of the datasets (NSC and sip63) is 
shown for (A) WG, (B) RefSeq and (C) miRBase.  Alignments were made with a 1 mismatch 
allowance. 
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Table 2: Effect of alignment reference on read quantification. 
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that did not correspond to a miRNA sequence, decreasing the chances of quantifying true miRNAs, 
thus increasing the false negative rate for quantification. For this reason, the miRBase reference 
was selected as the best reference to use for alignment. 
 In order to determine the optimal normalization method for our miRNA sequencing 
datasets, miRNA read counts were normalized using each of four normalization methods: RPKM, 
TPM, TC, and TMM. Table 3 lists the major differences between the chosen methods. To compare 
the effect of each of the normalization methods on the dataset, miRNA with read counts greater 
than or equal to 10 reads (recommended by Partek as a low expression threshold) were log-
transformed and the distribution between the raw and normalized reads datasets were assessed 
using boxplots for each of the various alignment references (Fig. 14-16). The raw read count 
dataset showed variation in the minimum, maximum and median values across conditional 
replicates (Fig. 14-16), reflecting the differences in sample size and composition across the 
replicates such as highly expressed miRNAs or a high amount of lowly expressed miRNAs that 
would affect the calculation of scaling factors, an artifact that is inherently present in the 
distribution of the datasets. 
 I evaluated the normalization methods’ effectiveness based on how well each method 
stabilized the median distribution after the normalization. Stabilization of the median distribution 
indicates that majority of the miRNAs from each of the replicates have similar expression values 
adhering to the underlying assumption that most miRNAs are not differentially expressed. For 
whole genome (Fig. 14) and RefSeq Transcripts (Fig. 15) aligned reads, each normalization 
method stabilized values at their minima, where all the minima values are equal. With regards to 
the median distribution, compared to the raw reads, each of the normalization methods remove 
some of the variation present in the samples, particularly for the sip63 samples, however RPKM  
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Normalization 
Method 
Normalize for 
gene length? 
Normalize for 
read depth? 
Compare 
across samples? 
Assume most 
genes are non-
DE? 
TMM No Yes Yes Yes 
TC No Yes No No 
RPKM Yes Yes No No 
TPM Yes Yes Yes No 
Table 3: Normalization method comparison. 
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Figure 14: Effect of normalization method on the distribution of Whole Genome aligned 
reads.  Log expression of miRNAs with reads greater than 10 in every sample are shown. For 
every normalization method, the first set of three bars represent NSC replicates 1, 2, and 3 and 
the second set of three bars represent sip63 replicates 1, 2, and 3.  
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Figure 15: Effect of normalization on the distribution for RefSeq aligned reads.  Log 
expression of miRNAs with reads greater than 10 in every sample are shown. For every 
normalization method, the first set of three bars represent NSC replicates 1, 2, and 3 and 
the second set of three bars represent sip63 replicates 1, 2, and 3.  
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Figure 16: Effect of normalization methods on the distribution of miRBase aligned reads.  
Log expression of miRNAs with reads greater than 10 in every sample are shown. For every 
normalization method, the first set of three bars represent NSC replicates 1, 2, and 3 and the 
second set of three bars represent sip63 replicates 1, 2, and 3.  
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and TPM normalizations increased the spread of the data, which would potentially affect 
downstream differential expression analysis. Between the four normalizations, TC and TMM 
showed stabilization of their median values within conditional replicates without increasing the 
overall spread of the distribution such as the effect of RPKM and TPM normalization. Irrespective 
of which alignment reference was used, RPKM and TPM normalized distributions were similar to 
each other, as expected, because TPM is a modified version of RPKM. By contrast, miRBase 
aligned reads (Fig. 16) exhibited a different distribution pattern, possibly due to more miRNAs 
being quantified. TC, RPKM, and TPM all had poor stabilization of the median values compared 
to the raw read counts, whereas TMM showed stabilization not just within the replicates, but across 
all 6 samples. Overall, it should be noted that miRBase aligned reads had a more compact 
interquartile range suggesting that the miRBase aligned dataset had a smaller variation in 
frequency of miRNA counts for each miRNA than compared to whole genome or RefSeq 
Transcripts aligned reads, suggesting that the miRBase alignment reference provides an advantage 
in accurately quantifying mapped reads, which in turn improves the accuracy of the downstream 
differential expression analysis. 
 I compared the effect of each normalization method using Principal Components Analysis 
(PCA). PCA plots for each normalization method are displayed in two principal component 
dimensions for ease of comparison between each of the normalization methods. Figure 17 displays 
PCA plots for each normalization method from the whole genome aligned reads. Similarly, 
Figures 18 and 19 display PCA plots for each normalization method from the RefSeq aligned 
reads and miRBase aligned reads, respectively. In every PCA plot of normalized data, I expected 
to see a clustering of replicates within their respective conditional groups, suggesting that 
normalization could group replicates together in an unsupervised manner. All the normalization 
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methods except TPM showed a clear separation of the replicate groups as compared to the raw 
reads (pre-normalization) (Fig. 17-19). Regardless of which alignment reference was used, TMM 
normalization showed the greatest degree of separation between the conditional groups (Fig. 17-
19). 
 
iii. Differential Expression Analysis 
 I performed differential expression analysis between sip63 and NSC replicates in order to 
identify miRNAs that are differentially regulated by DNp63a. I tested two different approaches to 
model our data: the multimodel approach and lognormal with shrinkage (LNS) approach (detailed 
in the materials and methods). The major difference between the two approaches is that multimodel 
chooses the response distribution model that best fits miRNA expression levels across the 
replicates. While this seems to provide the best description of a given miRNA’s expression pattern, 
it does not necessarily translate to the underlying trend in the population and can potentially over 
fit the data. LNS, however, ensures higher reproducibility in obtaining similar results based on 
pooling variance information across all genes, resulting in a higher, more reproducible study, 
especially under low replicate experiments. This is similar to the “limma trend” method from the 
limma package (Law, Chen et al. 2014). With any given RNA-Seq experiment, it is important to 
account for two main sources of variation: technical variation, a measure of error inherent to the 
sequencing technology and sample preparation, and biological variation, a representation of the 
heterogeneity among samples in similar treatment groups (Wu, Wang et al. 2013). I reasoned that 
the appropriate model would be one which accounts for the effect of gene-specific dispersion. The 
LNS approach uses an empirical Bayes method that better estimates gene-specific dispersion by  
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Figure 17: Principal component analysis of whole genome aligned samples before and 
after normalization. Variation in dot size corresponds to the biological replicate. Blue dots 
denote NSC samples and red dots denote sip63 samples.  
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Figure 18: Principal component analysis of RefSeq aligned samples before and after 
normalization. Variation in dot size corresponds to the biological replicate. Blue dots denote 
NSC samples and red dots denote sip63 samples.  
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Figure 19: Principal component analysis of miRBase aligned samples before and after 
normalization. Variation in dot size corresponds to the biological replicate. Blue dots denote 
NSC samples and red dots denote sip63 samples.  
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combining information about variance from other genes to improve the estimation process, 
resulting in improved DE detection and lower false-positive rates (Wu, Wang et al. 2013). I chose 
lognormal with shrinkage as the best response distribution as it accounts for the effect of gene-
specific dispersion in an experiment, thus improving reproducibility across multiple experiments. 
Tables 4 and 5 show the number of significantly differentially expressed miRNAs based 
on the alignment reference and normalization method used for both approaches. Similar to the 
box-plot distribution comparisons, whole genome and RefSeq Transcripts aligned datasets yielded 
a similar number of miRNAs that were considered to be significantly differentially expressed, 
while miRBase aligned reads had a considerably higher number of miRNA that are deemed 
significantly differentially expressed. This suggests that mapping to whole genome and RefSeq 
Transcripts references results in a large portion of low expressed miRNAs being filtered during 
the quantification step that would otherwise have information regarding its differential expression. 
There were subtle differences in the number of miRNAs that were significantly differentially 
expressed between multimodel and LNS approach for the whole genome and RefSeq transcripts 
alignment references, wherein the significant DE miRNAs from LNS were a subset of the 
significant DE miRNAs from multimodel.  
 I specifically considered the list of significantly differentially expressed miRNAs obtained 
from aligning to miRBase and normalizing miRNA counts using TMM from the LNS approach 
and assessed the overall performance of that pipeline. Figure 20 shows a heat map clustered by 
sample and feature using a Euclidean distance metric and average clustering metric for the 191 
differentially expressed miRNAs that were identified. Beneath the heat map is a dendrogram 
showing hierarchical clustering of the samples. Replicates 1 and 2 in either conditional group are 
more similar than replicate 3 as is shown. The heat map shows a distinct signature of miRNA  
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Table 4: Number of differentially expressed miRNA predicted using the multimodel 
distribution model for each normalization method for each alignment reference generated 
using the best model approach.  
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Table 5: Number of differentially expressed miRNA predicted by the log-normal with 
shrinkage distribution model for each normalization method for each alignment reference.  
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Figure 20: Heat map and dendrogram of significant DE miRNAs and pathways they affect. 
Significant DE miRNAs chosen from miRBase aligned, TMM normalized from LNS approach. 
A) Heat map and dendrogram generated in Partek flow. B) Pathways affected by miRNAs 
upregulated in the absence of p63. C) Pathways affected by miRNAs downregulated in the 
absence of p63. 
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expression profile as a result of silencing p63. When ΔNp63α is silenced, a subset of miRNAs is 
upregulated whose target mRNAs encode components in pathways such as Notch signaling and 
p53. Conversely, when ΔNp63α is silenced, a subset of miRNAs is downregulated who target 
mRNAs encode for components in pathways related to cancer and PI3K-AKT signaling pathway.  
 
iv. Validation of significantly differentially expressed miRNAs 
 I obtained the list of 191 differentially expressed miRNAs from miRBase aligned, TMM 
normalized reads, filtered by a significant p-value of less than or equal to 0.05 (Table 6). miRNAs 
that had high reads (>100) were considered as potential candidates to validate for the purposes of 
confirming my small RNA-Seq DE results as well as assessing the robustness of the established 
pipeline. Out of these miRNAs, those that were not previously shown to be regulated by p63 were 
shortlisted for validation for novel discovery. 15 miRNAs were selected to be validated via qRT-
PCR (Table 7). miRs-103a-3p, 149-5p, 18a-5p, 19b-1-5p, 590-5p, 598-3p, 7-5p, 708-5p, 744-5p, 
and 93-5p were all downregulated when ΔNp63α was silenced, thus confirming the DE results 
detected by small RNA-Seq (Fig. 22). By contrast, let-7c-5p, let-7e-5p, and miR-20a-5p did not 
appear to be regulated as predicted by our small RNA-Seq pipeline’s DE analysis.  
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miRNA ID Avg NSC (reads) Avg sip63 (reads) MultiModel p-value 
MultiModel 
Fold-Change 
hsa-let-7a-3p 320 +/- 25 160 +/- 11 0.0026 -2.00 
hsa-let-7c-5p 2880 +/- 369 1901 +/- 427 0.0346 -1.52 
hsa-let-7d-3p 512 +/- 180 304 +/- 50 0.0493 -1.68 
hsa-let-7d-5p 10425 +/- 1839 5570 +/- 245 0.0039 -1.87 
hsa-let-7e-5p 7740 +/- 1076 5265 +/- 712 0.0479 -1.47 
hsa-let-7f-1-3p 513 +/- 97 332 +/- 72 0.0422 -1.55 
hsa-miR-100-5p 7757 +/- 638 4728 +/- 1538 0.0190 -1.64 
hsa-miR-101-3p 1225 +/- 134 820 +/- 164 0.0384 -1.49 
hsa-miR-103a-2-5p 118 +/- 16 67 +/- 27 0.0337 -1.75 
hsa-miR-103a-3p 9524 +/- 1779 5177 +/- 239 0.0050 -1.84 
hsa-miR-103b 9524 +/- 1779 5177 +/- 239 0.0050 -1.84 
hsa-miR-106a-5p 829 +/- 76 510 +/- 48 0.0137 -1.63 
hsa-miR-107 1545 +/- 323 823 +/- 91 0.0044 -1.88 
hsa-miR-10a-3p 299 +/- 95 706 +/- 298 0.0049 2.36 
hsa-miR-10b-3p 8 +/- 3 27 +/- 6 0.0057 3.41 
hsa-miR-10b-5p 47 +/- 6 20 +/- 12 0.0189 -2.32 
hsa-miR-1180-3p 342 +/- 62 147 +/- 53 0.0017 -2.33 
hsa-miR-1199-3p 34 +/- 10 76 +/- 16 0.0096 2.23 
hsa-miR-1227-5p 13 +/- 4 3 +/- 2 0.0179 -4.21 
hsa-miR-1307-3p 279 +/- 42 176 +/- 20 0.0331 -1.59 
hsa-miR-130a-3p 3587 +/- 573 2351 +/- 550 0.0363 -1.53 
hsa-miR-138-5p 881 +/- 77 511 +/- 93 0.0085 -1.72 
hsa-miR-144-5p 56 +/- 10 30 +/- 6 0.0378 -1.85 
hsa-miR-146b-3p 14 +/- 6 34 +/- 10 0.0248 2.35 
hsa-miR-149-5p 796 +/- 56 450 +/- 27 0.0051 -1.77 
hsa-miR-152-3p 103 +/- 28 38 +/- 21 0.0039 -2.68 
hsa-miR-155-3p 59 +/- 28 20 +/- 18 0.0292 -2.90 
hsa-miR-17-3p 1346 +/- 130 895 +/- 71 0.0300 -1.50 
hsa-miR-181a-2-3p 328 +/- 30 210 +/- 81 0.0429 -1.56 
hsa-miR-181b-3p 76 +/- 22 42 +/- 13 0.0479 -1.82 
hsa-miR-181b-5p 1639 +/- 333 946 +/- 108 0.0094 -1.73 
hsa-miR-182-5p 877 +/- 226 554 +/- 118 0.0393 -1.58 
hsa-miR-185-5p 3092 +/- 499 1656 +/- 106 0.0029 -1.87 
hsa-miR-188-5p 42 +/- 2 22 +/- 6 0.0374 -1.91 
hsa-miR-18a-5p 13957 +/- 642 7916 +/- 1304 0.0066 -1.76 
hsa-miR-1908-5p 28 +/- 10 53 +/- 9 0.0415 1.87 
Table 6: List of miRNAs identified as significantly differently expressed by the small 
RNA-Seq pipeline. P-value and fold change for each miRNA is listed.  
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hsa-miR-191-5p 4326 +/- 640 2729 +/- 1036 0.0291 -1.59 
hsa-miR-194-3p 249 +/- 100 101 +/- 36 0.0048 -2.45 
hsa-miR-1973 9 +/- 7 21 +/- 8 0.0487 2.39 
hsa-miR-19b-1-5p 208 +/- 26 122 +/- 20 0.0200 -1.71 
hsa-miR-205-3p 575 +/- 235 277 +/- 39 0.0089 -2.08 
hsa-miR-205-5p 229055 +/- 40315 104386 +/- 18851 0.0042 -2.19 
hsa-miR-20a-5p 39907 +/- 3031 25285 +/- 3097 0.0303 -1.58 
hsa-miR-210-3p 1505 +/- 287 735 +/- 131 0.0019 -2.05 
hsa-miR-211-5p 47 +/- 9 15 +/- 12 0.0078 -3.06 
hsa-miR-212-5p 12 +/- 3 43 +/- 11 0.0015 3.68 
hsa-miR-23c 11275 +/- 1837 6754 +/- 595 0.0140 -1.67 
hsa-miR-24-3p 11664 +/- 3552 6237 +/- 102 0.0112 -1.87 
hsa-miR-27a-5p 261 +/- 12 137 +/- 28 0.0062 -1.90 
hsa-miR-28-3p 973 +/- 154 641 +/- 113 0.0377 -1.52 
hsa-miR-2909 10 +/- 9 24 +/- 1 0.0229 2.48 
hsa-miR-299-3p 74 +/- 14 33 +/- 21 0.0120 -2.25 
hsa-miR-29b-3p 69244 +/- 3231 41781 +/- 6427 0.0229 -1.66 
hsa-miR-29c-3p 3323 +/- 322 2269 +/- 190 0.0387 -1.46 
hsa-miR-29c-5p 93 +/- 33 44 +/- 11 0.0206 -2.10 
hsa-miR-3130-3p 34 +/- 12 4 +/- 4 0.0005 -8.18 
hsa-miR-3135a 11 +/- 5 1 +/- 0 0.0050 -10.81 
hsa-miR-3140-3p 51 +/- 13 24 +/- 6 0.0233 -2.12 
hsa-miR-3145-5p 22 +/- 2 52 +/- 21 0.0155 2.40 
hsa-miR-3160-3p 5 +/- 5 16 +/- 6 0.0258 3.09 
hsa-miR-3160-5p 18 +/- 7 5 +/- 5 0.0126 -3.81 
hsa-miR-3164 3 +/- 2 12 +/- 5 0.0438 3.45 
hsa-miR-3184-5p 72 +/- 28 31 +/- 11 0.0173 -2.33 
hsa-miR-3190-3p 1 +/- 0 14 +/- 11 0.0130 12.20 
hsa-miR-3192-5p 16 +/- 6 32 +/- 6 0.0467 2.00 
hsa-miR-3194-5p 13 +/- 6 29 +/- 9 0.0427 2.19 
hsa-miR-3196 10 +/- 5 24 +/- 9 0.0475 2.34 
hsa-miR-320a 1624 +/- 121 940 +/- 188 0.0075 -1.73 
hsa-miR-320b 948 +/- 100 554 +/- 115 0.0099 -1.71 
hsa-miR-320c 191 +/- 34 114 +/- 14 0.0276 -1.67 
hsa-miR-324-3p 35 +/- 5 17 +/- 8 0.0446 -2.01 
hsa-miR-330-3p 49 +/- 16 23 +/- 11 0.0353 -2.09 
hsa-miR-339-5p 2047 +/- 879 1142 +/- 388 0.0348 -1.79 
hsa-miR-3529-3p 12104 +/- 4039 5266 +/- 1076 0.0020 -2.30 
hsa-miR-363-5p 84 +/- 10 32 +/- 5 0.0017 -2.64 
hsa-miR-3649 9 +/- 5 25 +/- 6 0.0173 2.75 
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hsa-miR-3677-3p 4 +/- 3 14 +/- 7 0.0429 3.20 
hsa-miR-3688-3p 18 +/- 27 42 +/- 30 0.0278 2.35 
hsa-miR-3689b-5p 2 +/- 2 10 +/- 3 0.0230 4.59 
hsa-miR-376c-5p 2 +/- 2 10 +/- 4 0.0323 4.15 
hsa-miR-377-3p 19 +/- 5 46 +/- 15 0.0143 2.43 
hsa-miR-378a-3p 4317 +/- 997 2303 +/- 226 0.0049 -1.87 
hsa-miR-378i 89 +/- 16 40 +/- 12 0.0083 -2.21 
hsa-miR-379-3p 44 +/- 14 19 +/- 4 0.0185 -2.32 
hsa-miR-3937 51 +/- 16 98 +/- 7 0.0150 1.92 
hsa-miR-422a 111 +/- 21 63 +/- 14 0.0339 -1.74 
hsa-miR-423-3p 1343 +/- 240 736 +/- 129 0.0058 -1.82 
hsa-miR-4298 40 +/- 3 84 +/- 11 0.0078 2.12 
hsa-miR-4302 6 +/- 4 19 +/- 7 0.0289 3.22 
hsa-miR-4317 26 +/- 8 10 +/- 7 0.0227 -2.66 
hsa-miR-4420 9 +/- 1 29 +/- 3 0.0053 3.10 
hsa-miR-4438 2 +/- 2 13 +/- 3 0.0083 5.60 
hsa-miR-4446-3p 2 +/- 2 11 +/- 6 0.0215 4.79 
hsa-miR-4453 10 +/- 5 2 +/- 2 0.0220 -5.40 
hsa-miR-4454 3498 +/- 525 2035 +/- 433 0.0097 -1.72 
hsa-miR-4477a 7 +/- 2 18 +/- 0 0.0338 2.52 
hsa-miR-4492 30 +/- 8 12 +/- 12 0.0377 -2.43 
hsa-miR-4494 4 +/- 3 22 +/- 16 0.0130 5.03 
hsa-miR-4498 102 +/- 62 228 +/- 105 0.0162 2.24 
hsa-miR-449b-5p 14 +/- 6 31 +/- 4 0.0360 2.12 
hsa-miR-449c-5p 15 +/- 4 6 +/- 6 0.0457 -2.57 
hsa-miR-4511 38 +/- 9 73 +/- 10 0.0195 1.95 
hsa-miR-4524a-3p 11 +/- 6 29 +/- 8 0.0254 2.52 
hsa-miR-4535 10 +/- 6 2 +/- 2 0.0344 -4.97 
hsa-miR-455-3p 964 +/- 328 535 +/- 271 0.0256 -1.80 
hsa-miR-4650-3p 87 +/- 31 45 +/- 25 0.0451 -1.95 
hsa-miR-4654 17 +/- 9 5 +/- 5 0.0365 -3.24 
hsa-miR-4658 5 +/- 4 14 +/- 6 0.0474 2.99 
hsa-miR-4676-3p 193 +/- 79 395 +/- 97 0.0062 2.05 
hsa-miR-4677-3p 33 +/- 9 15 +/- 2 0.0346 -2.16 
hsa-miR-4700-5p 2 +/- 2 8 +/- 2 0.0354 4.04 
hsa-miR-4705 15 +/- 8 47 +/- 14 0.0047 3.05 
hsa-miR-4722-3p 46 +/- 9 24 +/- 11 0.0425 -1.95 
hsa-miR-4727-3p 9 +/- 7 23 +/- 1 0.0338 2.63 
hsa-miR-4732-5p 123 +/- 29 59 +/- 9 0.0090 -2.06 
hsa-miR-4734 4 +/- 2 13 +/- 2 0.0262 3.51 
hsa-miR-4740-5p 23 +/- 8 10 +/- 5 0.0475 -2.36 
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hsa-miR-4750-5p 99 +/- 20 165 +/- 49 0.0468 1.68 
hsa-miR-4758-3p 42 +/- 3 75 +/- 11 0.0343 1.78 
hsa-miR-4780 21 +/- 10 8 +/- 3 0.0498 -2.54 
hsa-miR-4800-5p 17 +/- 7 4 +/- 3 0.0150 -4.07 
hsa-miR-483-5p 102 +/- 24 56 +/- 16 0.0318 -1.82 
hsa-miR-497-5p 36 +/- 7 10 +/- 5 0.0033 -3.62 
hsa-miR-5002-3p 19 +/- 5 50 +/- 11 0.0075 2.56 
hsa-miR-5006-3p 20 +/- 13 4 +/- 0 0.0111 -4.90 
hsa-miR-503-5p 503 +/- 133 249 +/- 42 0.0051 -2.02 
hsa-miR-505-5p 66 +/- 17 35 +/- 8 0.0346 -1.89 
hsa-miR-507 6 +/- 1 17 +/- 3 0.0238 2.92 
hsa-miR-5089-5p 17 +/- 8 36 +/- 4 0.0292 2.10 
hsa-miR-509-3-5p 3 +/- 2 14 +/- 3 0.0167 4.06 
hsa-miR-5196-3p 90 +/- 27 34 +/- 8 0.0030 -2.68 
hsa-miR-520f-3p 8 +/- 3 2 +/- 2 0.0474 -3.90 
hsa-miR-539-3p 18 +/- 12 41 +/- 12 0.0238 2.30 
hsa-miR-548ah-5p 15 +/- 6 46 +/- 16 0.0061 3.07 
hsa-miR-548as-5p 13 +/- 9 30 +/- 8 0.0369 2.22 
hsa-miR-548ay-5p 1 +/- 0 6 +/- 2 0.0377 6.23 
hsa-miR-548o-3p 20 +/- 5 41 +/- 11 0.0399 2.03 
hsa-miR-553 15 +/- 2 35 +/- 10 0.0243 2.28 
hsa-miR-557 22 +/- 9 8 +/- 1 0.0345 -2.70 
hsa-miR-5584-3p 12 +/- 5 3 +/- 2 0.0297 -3.79 
hsa-miR-5681a 16 +/- 11 34 +/- 11 0.0397 2.19 
hsa-miR-5693 7 +/- 3 29 +/- 1 0.0017 4.30 
hsa-miR-5697 93 +/- 22 169 +/- 45 0.0272 1.81 
hsa-miR-5705 23 +/- 7 8 +/- 7 0.0240 -2.99 
hsa-miR-590-3p 431 +/- 197 187 +/- 78 0.0116 -2.30 
hsa-miR-590-5p 1270 +/- 211 650 +/- 41 0.0022 -1.95 
hsa-miR-598-3p 189 +/- 65 106 +/- 54 0.0455 -1.79 
hsa-miR-6068 13 +/- 6 4 +/- 3 0.0383 -3.36 
hsa-miR-6078 21 +/- 17 45 +/- 9 0.0275 2.12 
hsa-miR-642a-5p 11 +/- 9 41 +/- 14 0.0093 3.93 
hsa-miR-6499-5p 2 +/- 2 12 +/- 2 0.0099 5.56 
hsa-miR-6516-3p 18 +/- 5 5 +/- 5 0.0207 -3.31 
hsa-miR-657 6 +/- 1 21 +/- 12 0.0176 3.69 
hsa-miR-664b-3p 16 +/- 4 6 +/- 3 0.0442 -2.57 
hsa-miR-671-5p 360 +/- 128 196 +/- 26 0.0282 -1.83 
hsa-miR-6729-5p 9 +/- 6 22 +/- 2 0.0357 2.31 
hsa-miR-6730-5p 54 +/- 16 89 +/- 3 0.0491 1.65 
hsa-miR-6732-3p 6 +/- 1 18 +/- 3 0.0161 3.13 
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hsa-miR-6733-5p 539 +/- 103 331 +/- 99 0.0311 -1.63 
hsa-miR-6772-5p 6 +/- 6 16 +/- 2 0.0352 2.68 
hsa-miR-6775-5p 63 +/- 12 33 +/- 12 0.0290 -1.92 
hsa-miR-6776-3p 13 +/- 7 29 +/- 4 0.0320 2.28 
hsa-miR-6793-3p 8 +/- 4 25 +/- 12 0.0296 2.92 
hsa-miR-6793-5p 23 +/- 15 46 +/- 11 0.0355 2.02 
hsa-miR-6797-3p 51 +/- 17 13 +/- 5 0.0011 -3.97 
hsa-miR-6811-5p 2 +/- 2 9 +/- 4 0.0377 4.40 
hsa-miR-6822-3p 29 +/- 6 64 +/- 31 0.0310 2.21 
hsa-miR-6827-5p 16 +/- 10 4 +/- 3 0.0355 -3.71 
hsa-miR-6833-3p 17 +/- 9 35 +/- 3 0.0428 1.99 
hsa-miR-6850-5p 38 +/- 8 95 +/- 43 0.0081 2.54 
hsa-miR-6865-5p 500 +/- 149 285 +/- 54 0.0187 -1.76 
hsa-miR-6893-5p 4 +/- 3 21 +/- 1 0.0055 4.68 
hsa-miR-7-5p 6650 +/- 2280 3482 +/- 742 0.0134 -1.91 
hsa-miR-708-5p 1977 +/- 83 1354 +/- 206 0.0398 -1.46 
hsa-miR-7108-3p 176 +/- 37 98 +/- 46 0.0337 -1.80 
hsa-miR-7151-5p 6 +/- 3 17 +/- 5 0.0351 2.77 
hsa-miR-7154-5p 10 +/- 5 25 +/- 9 0.0276 2.61 
hsa-miR-744-5p 506 +/- 64 281 +/- 56 0.0076 -1.80 
hsa-miR-769-5p 518 +/- 99 315 +/- 87 0.0284 -1.64 
hsa-miR-770-5p 14 +/- 6 33 +/- 14 0.0390 2.39 
hsa-miR-7844-5p 5 +/- 0 15 +/- 4 0.0264 3.15 
hsa-miR-7974 59 +/- 21 28 +/- 3 0.0314 -2.11 
hsa-miR-8086 17 +/- 8 38 +/- 6 0.0255 2.20 
hsa-miR-92a-1-5p 69 +/- 28 25 +/- 11 0.0086 -2.71 
hsa-miR-92b-3p 615 +/- 157 383 +/- 110 0.0393 -1.61 
hsa-miR-93-3p 307 +/- 64 156 +/- 5 0.0054 -1.96 
hsa-miR-93-5p 13999 +/- 2668 8068 +/- 1069 0.0118 -1.74 
hsa-miR-942-3p 34 +/- 24 12 +/- 4 0.0378 -2.78 
hsa-miR-944 114 +/- 24 53 +/- 13 0.0076 -2.14 
hsa-miR-95-5p 13 +/- 6 28 +/- 4 0.0434 2.09 
hsa-miR-99b-5p 1571 +/- 131 885 +/- 148 0.0049 -1.77 
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Table 7: miRNAs selected for validation based on p ≤ 0.05 significance and with no 
known link to p63.  
	
64	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
65	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: qRT-PCR validation of candidate miRNAs. 1 µg of total RNA was reverse 
transcribed into cDNA and using AODs specific for the candidate miRNAs and quantitative 
Real-Time PCR was performed. Expression levels were normalized to RNU48. qRT-PCR 
was done in triplicate for each specific miRNA for each of the 3 biological replicates of 
NSC and sip63 transfected HaCaT cells. Fold change (FC) and p value information from 
small RNA-Seq DE analysis listed above. * = p £ 0.1, ** = p £ 0.05, NS = not significant. 
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IV. DISCUSSION 
 
A. Regulation of ΔNp63α by JNK 
 In this study, I investigated a novel role for JNK in regulating ΔNp63α in response to 
genotoxic and carcinogenic stress. A previous study showed that UV damage results in down-
regulation of ΔNp63α as a result of phosphorylation of ΔNp63α by p38 MAPK (Liefer, Koster et 
al. 2000, Papoutsaki, Moretti et al. 2005, Westfall, Joyner et al. 2005). Interestingly, UV exposure 
led to the activation of not only p38 MAPK signaling pathway, but also the JNK signaling pathway. 
Specifically, JNK was not ruled out as a potential candidate kinase that phosphorylates ΔNp63α.  
 I showed that stress-mediated activation of JNK by UV and anisomycin treatment 
correlated with a mobility shift of ΔNp63α, suggesting phosphorylation of ΔNp63α, which 
occurred as early as 30 minutes following stress induction. Furthermore, co-expression of ΔNp63α 
with JNK1 and JNK2 enhanced the ΔNp63α mobility shift. Interestingly, a non-mobility shifted 
ΔNp63α band or non-phosphorylated form was not observed, suggesting that most, if not all, of 
the protein was being phosphorylated. An in vitro kinase assay with recombinant active JNK1 and 
JNK2 and recombinant ΔNp63α proteins resulted in ΔNp63α’s phosphorylation, suggesting that 
JNK can bind and phosphorylate ΔNp63α at various residues, which implicates this kinase as a 
regulator of p63 stability (Chen, Wang et al. 1996). Interestingly, JNK1 had greater 
phosphorylation effect than JNK2, despite using equal quantities of the kinases in the assay 
suggesting that JNK1 may have a greater binding affinity for ΔNp63α as compared to JNK2. In 
the context of non-melanoma skin cancers, this would allow for a cell to undergo apoptosis as 
opposed to becoming cancerous as JNK1 is known to have tumor suppressor function (Bode and 
Dong 2007). Specifically, based on our studies, JNK1 would appear to have a more active role in 
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mediating apoptosis by phosphorylating ΔNp63α, tagging it for ubiquitin-mediated proteasomal 
degradation.  
 There is significant homology between p53 family members (Buschmann, Potapova et al. 
2001) and as shown in Figure 6, JNK targeted residues in TAp73α were highly conserved in 
ΔNp63α. Mass spectrometry analysis of H1299 cells transfected with ΔNp63α and treated with 
UV confirmed phosphorylation at several residues which are conserved between ΔNp63α and 
TAp73 (S53, S66, S369, T297 and T444). While mutation of these residues individually did not 
prevent the UVC or anisomycin induced mobility shift in ΔNp63α, it is possible that these residues 
are phosphorylated by active JNK but do not individually cause a mobility shift detectable under 
the SDS-PAGE conditions used. To address this possibility, a phospho-deficient mutant ΔNp63α 
containing seven mutated residues was constructed to maximize the likelihood of seeing a 
reversion of the electrophoretic mobility shift in ΔNp63α. Expressing this mutant in H1299 cells 
with UV and Anisomycin treatment showed a stabilization of ΔNp63α protein levels, despite a 
slight mobility shift, suggesting that JNK-mediated phosphorylation is likely due to a combination 
of sites being phosphorylated and that the phospho-deficient ΔNp63α mutant is no longer targeted 
for degradation. Alternatively, it cannot be ruled out that mutation of these 7 residues altogether 
could drastically alter the structure of the protein, and thus, disrupt the interaction between JNK 
and ΔNp63α. As well, many of these sites are contained in regions that are essential for 
phosphorylation by p38 (Papoutsaki, Moretti et al. 2005). Differentiating the specific potential 
residues could be accomplished by creating deletion constructs of recombinant p63 and performing 
in vitro kinase assays with recombinant active JNK1 or JNK2 to further resolve the specific regions 
JNK targets and pursuing the serines and threonines within those regions for mutagenesis. 
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However, my results highlight a previously unrecognized role for JNK signaling as a regulator of 
ΔNp63α phosphorylation and its subsequent proteasomal degradation following cellular stress. 
 Future studies will be conducted to closely examine the relationship between active JNK 
and p63. One potential study will involve using phosphatase controls to show reversion of the 
electrophoretic mobility shift upon UV or Anisomycin treatment, which would confirm that 
ΔNp63α is phosphorylated by JNK. Another study will involve studying the association of 
ΔNp63α and JNK by using immunoprecipitation to test whether JNK binds to ΔNp63α alone or 
in complex. p73 would be used as positive control as its interaction with JNK is previously known 
(Jones, Dickman et al. 2007). In addition, the contribution of other MAPK members to the 
phosphorylation of ΔNp63α will also be explored. This will be done in a preliminary study 
utilizing a kinase library. 
 
B. ΔNp63α global regulation of miRNA 
 Next-generation sequencing technology has revolutionized the amount of information that 
can be gathered about the genetic make-up of organisms, however the platform for data analysis 
is still a rapidly developing field that requires more studies to accurately confirm that our methods 
of analysis mirror what is happening biologically. Specifically, there are very few studies that 
empirically test a next-generation sequencing pipeline workflow parameters for identifying 
differentially regulated miRNAs for small RNA-Seq data. I aimed to establish an optimized 
workflow that is suitable for miRNA sequencing data. In this study, NSC and sip63 HaCaT cells 
were used to optimize next generation sequencing data processing parameters and validate a small 
RNA-Seq analysis pipeline. The validated pipeline utilizes alignment and quantitation to the 
miRBase reference, normalization using TMM and a lognormal with shrinkage response 
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distribution model for the identification of differentially expressed miRNA and has the following 
benefits: (1) robust annotation and quantitation of miRNA reads compared to alignment using the 
RefSeq (transcriptome) and Whole Genome reference databases, particularly miRNA with low 
expression, (2) effective normalization of read distributions leading to the robust clustering of 
experimental replicates, and (3) concurrence with RT-PCR data. This validated pipeline was used 
to identify novel ΔNp63α-regulated miRNA which have predicted mRNA targets in cancer 
signaling pathways. Further characterization of these miRNA and their mRNA targets may provide 
mechanistic insight into the progression of non-melanoma skin cancer.  
 Three key steps were taken into consideration for the optimization of the workflow: 
alignment reference, normalization, and response distribution model for DE analysis. I found that 
the choice of alignment reference has a major influence on the number of miRNAs that are 
identified downstream during DE detection. I found that alignments using whole genome and 
RefSeq Transcripts references yielded a very similar number of differentially expressed miRNAs, 
whereas alignments using the miRBase reference resulted in a significantly higher number of 
differentially expressed miRNAs. It is also important to note that alignment to whole genome and 
RefSeq Transcripts references yielded a large number of aligned reads that did not correspond to 
a miRNA. Since the default alignment reporting options of the bowtie algorithm were used, with 
whole genome and RefSeq Transcripts, there was a higher chance of reporting a valid alignment 
that did not correspond to a miRNA as opposed to reporting one that did correspond with a miRNA, 
resulting in a higher false negative rate.  
 Given that miRNA play a regulatory role in gene expression, it is probable that miRNAs 
are increased or decreased in expression rather than being completely switched on or off. Aligning 
to miRBase better captures these low basally expressed miRNAs when comparing the differences 
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in miRNA count distribution. Many more miRNAs were accurately quantified as lowly expressed 
as opposed to not being quantified at all. This would affect downstream DE detection since even 
low expressed miRNAs could play a huge role in regulating downstream target mRNA (Tam, Tsao 
et al. 2015). As well, although the number of total reads that aligned to the miRBase reference was 
far lower compared to alignment to whole genome or RefSeq Transcripts, a 100% of those aligned 
reads were quantified as miRNAs. This is due to the usage of default alignment reporting options 
(reporting 1 valid alignment per read – the first valid alignment Bowtie happens to come across), 
meaning there was less of a chance of miRBase aligned reads reporting non-specifically aligned 
reads as would be the case with whole genome or RefSeq Transcripts aligned reads and ultimately 
being excluded during the quantification process. 
 Although the normalization step was not initially considered to be crucial in the data 
analysis process, a similar realization has taken hold with RNA-Seq data much in the same manner 
of the necessity of normalization with regards to microarray data. DE detection downstream is 
highly dependent on normalization (Tam, Tsao et al. 2015). We evaluated four different 
normalization methods (TC, RPKM, TPM, and TMM) on our dataset to identify the most suitable 
method for normalizing small RNA-Seq data. Upon considering the effects of normalization by 
relative log expression distribution and clustering of conditional replicates via PCA, I provide 
compelling evidence that TMM is the most suitable for normalizing small RNA-Seq data. TMM 
is also supported by previous studies as a robust normalization method (Dillies, Rau et al. 2013, 
Tam, Tsao et al. 2015).  
 	Differential expression analysis performed using the multimodel or lognormal with 
shrinkage (LNS) approaches identified a core set of miRNA in our sip63 samples which were 
differentially expressed relative to NSC samples. The possibility that the multimodel approach 
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over-fit the data yielding an increased false-positive rate could not be ruled out. ERCC spike-in 
control RNAs which are routinely used as calibrators for RNA-Seq experiments are not currently 
configured for use in small RNA-Seq experiments on the Ion Torrent sequencing platform. Thus, 
assessment of the false-positive rate for the multimodel approach would require extensive qRT-
PCR validation, and is beyond the scope of this study. Rather, the LNS approach can be used as a 
conservative approach for identifying candidate differentially expressed miRNA. 
Of the novel p63-regulated miRNA identified and validated in this study, several have 
known roles in cancer. miR-18a-5p plays an oncogenic role in nasopharyngeal cancer by 
regulating E-cadherin and K-ras (Luo, Dai et al. 2013), miR-93-5p is elevated in colorectal cancer, 
and miR-19b-1-5p is downregulated in CD44+ cervical cancer cells which express increased p63 
levels, although no link was implied (Xiao, Zhou et al. 2014). Similarly, amplification of the cluster 
containing miR-20a-5p has been observed in leukemia but only miR-92a, another miRNA in the 
cluster, is known to regulate p63. Other miRNA identified in this study mediate cancer signaling, 
such as miR-590-5p which attenuates the TGFβ signaling pathway through down-regulation of 
SMAD3 and miR-7-5p which targets EGFR (Vasanthan, Govindasamy et al. 2015, Jafarzadeh and 
Soltani 2016). Nothing has been published regarding the functional roles or regulation for the 
remaining miRNA identified in this study. It is our hope that these miRNA and additional targets 
identified by our small RNA-Seq pipeline will be a source of biomarkers and therapeutic targets 
for p63-related pathologies and provide critical insight into the role played by p63 in cancer. 
 Within our pipeline workflow, there are, however, challenges to be overcome. In particular, 
tweaking alignment options to report the best to worst alignments for reads could improve the 
overall quantification of miRNAs. The current limitations of my analysis were the number of 
replicates I had for each conditional group. While 3 biological replicates may be enough from the 
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perspective of a biologist, it is not a big enough sample size to achieve results of high statistical 
power. Thus, in order to further optimize the pipeline that I have established, future small RNA-
Seq experiments involving more replicates for each conditional group would improve the ability 
for differentially expressed miRNAs to be detected. With regards to novel discovery of p63 
biology, miRNAs that were validated could be selected for studies using cell cultures to assess 
whether its target mRNAs are being regulated and what pathways are being affected. 
In conclusion, my investigation of the various alignment reference databases (whole 
genome, RefSeq and miRBase), normalization methods (TC, RPKM, TPM, and TMM), and 
response distribution model for DE analysis (Multimodel and LNS) highlights the potential impact 
of each step on the analysis of small RNA-Seq data. While it is important to experiment with 
pipeline parameters to accommodate differences in sample library composition and confirm data 
output by qRT-PCR, I propose that using the Bowtie aligner and the miRBase reference for 
alignment and quantification as well as the TMM normalization method provide a robust standard 
pipeline for small RNA-Seq analyses. 
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